MAF1 suppresses AKT‐mTOR signaling and liver cancer through activation of PTEN transcription

Yue Li, Chi Kwan Tsang, Suihai Wang, Xiao‐Xing Li, Yang Yang, Liwu Fu, Wenlin Huang, Ming Li, Hui‐Yun Wang, X.F. Steven Zheng – 22 February 2016 – The phosphatidylinositol 3‐kinase/phosphatidylinositol 3,4,5‐trisphosphate 3‐phosphatase/protein kinase B/mammalian target of rapamycin (PI3K‐PTEN‐AKT‐mTOR) pathway is a central controller of cell growth and a key driver for human cancer. MAF1 is an mTOR downstream effector and transcriptional repressor of ribosomal and transfer RNA genes.

Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans

Lei Li, Li Che, Kevin M. Tharp, Hyo‐Min Park, Maria G. Pilo, Dan Cao, Antonio Cigliano, Gavinella Latte, Zhong Xu, Silvia Ribback, Frank Dombrowski, Matthias Evert, Gregory J. Gores, Andreas Stahl, Diego F. Calvisi, Xin Chen – 22 February 2016 – Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are the most prevalent types of primary liver cancer. These malignancies have limited treatment options, resulting in poor patient outcomes. Metabolism reprogramming, including increased de novo lipogenesis, is one of the hallmarks of cancer.

Atorvastatin and fluvastatin are associated with dose‐dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES

Tracey G. Simon, Hector Bonilla, Peng Yan, Raymond T. Chung, Adeel A. Butt – 18 February 2016 – Statins are associated with delayed fibrosis progression and a reduced risk of hepatocellular carcinoma (HCC) in chronic hepatitis C virus (HCV). Limited data exist regarding the most effective type and dose of statin in this population. We sought to determine the impact of statin type and dose upon fibrosis progression and HCC in patients with HCV.

Subscribe to